Last reviewed · How we verify
Immunosuppression reduction/modification + intravenous immunoglobulin
This therapeutic approach reduces immunosuppressive medication burden while administering intravenous immunoglobulin to modulate immune tolerance in transplant recipients.
This therapeutic approach reduces immunosuppressive medication burden while administering intravenous immunoglobulin to modulate immune tolerance in transplant recipients. Used for Organ transplant rejection prevention with reduced immunosuppression burden.
At a glance
| Generic name | Immunosuppression reduction/modification + intravenous immunoglobulin |
|---|---|
| Also known as | Human immunoglobulin |
| Sponsor | The University of Queensland |
| Drug class | Immunomodulatory combination therapy |
| Modality | Small molecule |
| Therapeutic area | Immunology / Transplantation |
| Phase | Phase 3 |
Mechanism of action
The strategy involves tapering or modifying standard immunosuppressive regimens (such as calcineurin inhibitors or antimetabolites) while simultaneously providing IVIG to enhance immune regulation and reduce rejection risk. IVIG contains pooled human antibodies that can suppress autoreactive B and T cells, promote regulatory T cell expansion, and modulate complement activation, potentially allowing safer reduction of toxic immunosuppressive drugs.
Approved indications
- Organ transplant rejection prevention with reduced immunosuppression burden
Common side effects
- Infusion reactions
- Headache
- Fever
- Rejection episodes
- Infection risk
Key clinical trials
- A Trial to Treat Polyomavirus Infections (BKPyV) in Kidney and Simultaneous Kidney Pancreas Transplant Recipients (PHASE3)
- Clinical Trial With Donor Modified Immune Cells in Living Donor Kidney Transplantation (PHASE2)
- Study Comparing Efficacy and Safety of Mycophenolate Mofetil (Cellcept) With Delayed Introduction of Sirolimus and Discontinuation of Cyclosporine, With Those of Mycophenolate Mofetil and Long Term Continuation of Cyclosporine in Renal Transplant Recipients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: